Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about DES: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
DES is a gene implicated in neurodegeneration research. Key relationships include: activates, implicated in, associated with. Associated with ALS, Aging, Als. Connected to 115 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | DES |
| Full Name | Desmin |
| Chromosome | 2q35 |
| Function | is a critical structural component of muscle cells[@paulin2004]. |
| Molecular Weight | 53 kDa |
| Amino Acids | 470 aa |
| Pathways | Angiogenesis, Apoptosis, Autophagy, Ferroptosis, Necroptosis |
| UniProt ID | P17661 |
| NCBI Gene ID | 1674 |
| Ensembl ID | ENSG00000175084 |
| OMIM | 125660 |
| GeneCards | DES |
| Human Protein Atlas | DES |
| N-terminal head domain (residues 1-99) | Contains phosphorylation sites and regulates filament assembly |
| Central rod domain (residues 100-411) | Consists of four alpha-helical segments (1A, 1B, 2A, 2B) separated by linkers, responsible for dimerization and filament assembly |
| Associated Diseases | Aging, Als, Alzheimer, Cancer, Cardiac, Cardiovascular |
| Interactions | AGING, AMPK, AND, APOPTOSIS, App, AUTOPHAGY |
| KG Connections | 196 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
DES["DES"]
SMOC2["SMOC2"]
DES -->|"co expressed with"| SMOC2
DSP["DSP"]
DES -->|"co expressed with"| DSP
GJA1["GJA1"]
DES -->|"co expressed with"| GJA1
myofibrillar_myopathy{"myofibrillar myopathy"}
DES -->|"causes"| myofibrillar_myopathy
Aging{"Aging"}
DES -->|"activates"| Aging
Ms{"Ms"}
DES -->|"activates"| Ms
Cancer{"Cancer"}
DES -->|"associated with"| Cancer
Als{"Als"}
DES -->|"therapeutic target"| Als
DES -->|"therapeutic target"| Aging
Tumor{"Tumor"}
DES -->|"therapeutic target"| Tumor
Longevity{"Longevity"}
DES -->|"therapeutic target"| Longevity
DES -->|"associated with"| Ms
MCU["MCU"]
MCU -->|"activates"| DES
SLC7A11["SLC7A11"]
SLC7A11 -->|"activates"| DES
BECN1["BECN1"]
BECN1 -->|"activates"| DES
GENES["GENES"]
GENES -->|"therapeutic target"| DES
AMPK["AMPK"]
AMPK -->|"activates"| DES
ABCB1["ABCB1"]
ABCB1 -->|"associated with"| DES
FAS["FAS"]
FAS -->|"interacts with"| DES
CASP8["CASP8"]
CASP8 -->|"interacts with"| DES
CASP6["CASP6"]
CASP6 -->|"interacts with"| DES
MITOCHONDRIAL_DYSFUNCTION["MITOCHONDRIAL DYSFUNCTION"]
MITOCHONDRIAL_DYSFUNCTION -->|"activates"| DES
APOPTOSIS["APOPTOSIS"]
APOPTOSIS -->|"activates"| DES
CANCER["CANCER"]
CANCER -->|"associated with"| DES
style DES fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| Myofibrillar Myopathy | causes | disease | 0.95 |
| GJA1 | co_expressed_with | gene | 0.80 |
| DSP | co_expressed_with | gene | 0.80 |
| SMOC2 | co_expressed_with | gene | 0.80 |
| Tumor | activates | disease | 0.75 |
| Als | associated_with | disease | 0.75 |
| Als | activates | disease | 0.75 |
| myofibrillar myopathy | causes | disease | 0.70 |
| Pain | associated_with | disease | 0.65 |
| Insulin Resistance | implicated_in | disease | 0.65 |
| Tumor | expressed_in | disease | 0.65 |
| ALS | expressed_in | disease | 0.65 |
| Aging | expressed_in | disease | 0.65 |
| Hypertension | implicated_in | disease | 0.65 |
| Obesity | implicated_in | disease | 0.65 |
| Inflammation | contributes_to | disease | 0.65 |
| Cardiac | implicated_in | disease | 0.65 |
| Ischemia | implicated_in | disease | 0.65 |
| Cancer | activates | disease | 0.65 |
| Als | inhibits | disease | 0.65 |
| Diabetes | implicated_in | disease | 0.65 |
| Cardiovascular | implicated_in | disease | 0.65 |
| Ms | interacts_with | disease | 0.65 |
| Cancer | interacts_with | disease | 0.65 |
| Hepatocellular Carcinoma | biomarker_for | disease | 0.65 |
| Cancer | biomarker_for | disease | 0.65 |
| Als | biomarker_for | disease | 0.65 |
| Carcinoma | biomarker_for | disease | 0.65 |
| Hepatitis | protects_against | disease | 0.65 |
| Infection | protects_against | disease | 0.65 |
| Als | protects_against | disease | 0.65 |
| ALS | activates | disease | 0.65 |
| ALS | biomarker_for | disease | 0.65 |
| Dementia | biomarker_for | disease | 0.65 |
| Alzheimer | associated_with | disease | 0.65 |
| Tumor | associated_with | disease | 0.65 |
| Tumor | biomarker_for | disease | 0.65 |
| Hepatitis | implicated_in | disease | 0.65 |
| Cancer | associated_with | disease | 0.65 |
| Als | therapeutic_target | disease | 0.65 |
| Aging | therapeutic_target | disease | 0.65 |
| Tumor | therapeutic_target | disease | 0.65 |
| Longevity | therapeutic_target | disease | 0.65 |
| Ms | associated_with | disease | 0.65 |
| Ms | therapeutic_target | disease | 0.65 |
| Cirrhosis | implicated_in | disease | 0.65 |
| Fibrosis | implicated_in | disease | 0.65 |
| Aging | associated_with | disease | 0.65 |
| Aging | activates | disease | 0.65 |
| Ms | activates | disease | 0.65 |
| Source | Relation | Type | Str |
|---|---|---|---|
| MICROTUBULES | associated_with | gene | 0.60 |
| AND | interacts_with | gene | 0.60 |
| AND | protects_against | gene | 0.60 |
| AGING | expressed_in | gene | 0.60 |
| GENES | expressed_in | gene | 0.60 |
| ONCOGENES | expressed_in | gene | 0.60 |
| INFLAMMATION | contributes_to | gene | 0.60 |
| SLC7A11 | activates | gene | 0.60 |
| BECN1 | activates | gene | 0.60 |
| VEGF | therapeutic_target | gene | 0.60 |
| P38 | inhibits | gene | 0.60 |
| BRCA1 | degrades | entity | 0.60 |
| MCU | activates | gene | 0.60 |
| DNAJB6 | associated_with | gene | 0.60 |
| SQSTM1 | associated_with | gene | 0.60 |
| FLNC | associated_with | gene | 0.60 |
| NBR1 | associated_with | gene | 0.60 |
| MYOT | associated_with | gene | 0.60 |
| P62 | associated_with | gene | 0.60 |
| BRCA1 | associated_with | gene | 0.60 |
| GENES | therapeutic_target | gene | 0.60 |
| AMPK | activates | gene | 0.60 |
| APOPTOSIS | activates | gene | 0.60 |
| CANCER | associated_with | gene | 0.60 |
| FERROPTOSIS | activates | gene | 0.60 |
| AUTOPHAGY | activates | gene | 0.60 |
| AGING | implicated_in | gene | 0.60 |
| APOPTOSIS | contributes_to | gene | 0.60 |
| INSULIN RESISTANCE | implicated_in | gene | 0.60 |
| AUTOPHAGY | associated_with | gene | 0.60 |
| PD-L1 | biomarker_for | gene | 0.60 |
| ABCB1 | associated_with | gene | 0.60 |
| TAU | biomarker_for | gene | 0.60 |
| BAD | therapeutic_target | gene | 0.60 |
| AND | associated_with | gene | 0.60 |
| AGING | therapeutic_target | gene | 0.60 |
| AND | biomarker_for | gene | 0.60 |
| MITOCHONDRIAL DYSFUNCTION | activates | gene | 0.60 |
| ALZHEIMER | associated_with | gene | 0.60 |
| AMYLOID | associated_with | gene | 0.60 |
| DNA | biomarker_for | gene | 0.60 |
| CANCER | biomarker_for | gene | 0.60 |
| AND | activates | gene | 0.60 |
| AGING | activates | gene | 0.60 |
| ONCOGENES | therapeutic_target | gene | 0.60 |
| FAS | interacts_with | gene | 0.60 |
| CASP8 | interacts_with | gene | 0.60 |
| CASP6 | interacts_with | gene | 0.60 |
| MACF1 | causes | gene | 0.60 |
| CHRNE | causes | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| Irisin effects on angiogenesis in human endothelial cells | exploratory | bone fracture | 0.900 | 0.00 | human umbilical vein endotheli | proposed | N/A |
| APOE4 association with TDP-43 pathology in AD | exploratory | Alzheimer's disease | 0.750 | 0.00 | human patients | proposed | N/A |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| ApoE4 Function in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $360,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Metal Ion Homeostasis Dysregulation in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] | Raulin AC, Doss SV, Trottier ZA, Ikezu T | Mol Neurodegener | 2022 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventin [PMID:30595089] | Brophy ML, Dong Y, Tao H, Yancey PG, Son | Circ Res | 2019 | 1 |
| Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical [PMID:28381441] | Shinohara M, Tachibana M, Kanekiyo T, Bu | J Lipid Res | 2017 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] | ["Barger S", "Moerman-Herzog A"] | Frontiers in molecular neurosc | 2026 | 0 |
| Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990] | Keller A | Annual review of physiology | 2026 | 0 |
| ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] | Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha | Frontiers in bioscience (Landm | 2026 | 0 |
| CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] | ["Wang M", "Niu D", "Zhang Q", "Tang Y", | International journal of biolo | 2026 | 0 |
| Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: [PMID:41921464] | Catino F, Castellana F, Zupo R, Giannocc | Artificial intelligence in med | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811] | Wang Y, Zhang Z, Cao L, Huang S, Huang X | J Ethnopharmacol | 2026 | 0 |
| Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710] | Yang X, Xiao JH, Li X, Liu RM, Yuan Q | J Ethnopharmacol | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning DES in their description or question text
Score: 0.718 · neurodegeneration · 2026-04-02
## Mechanistic Overview Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides starts from the claim that modulating
Score: 0.708 · synaptic biology · 2026-04-21
## Mechanistic Overview TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Re
Score: 0.698 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The pathogenic mechanism underlying C9orf72-associated amyotrophic lateral sclero
Score: 0.690 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The pathogenesis of frontotemporal dementia with GRN mutations (FTD-GRN) involves
Score: 0.637 · Alzheimer's disease · 2026-04-04
## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the
Score: 0.621 · neurodegeneration · 2026-04-02
## Mechanistic Overview Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery starts from th
Score: 0.604 · neurodegeneration · 2026-04-15
## Mechanistic Overview DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization starts fr
Score: 0.600 · unknown disease · 2026-04-26
Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blo
Score: 0.580 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) signaling cascade re
Score: 0.580 · neuroinflammation · 2026-04-21
## Mechanistic Overview Astrocyte cGAS/STING Activation Converts Protective into Destructive Neuroinflammation starts fr
Score: 0.580 · neurodegeneration · 2026-04-24
A more mechanistic but less translationally mature possibility is that G2019S does not strongly alter total phospho-Rab
Score: 0.578 · neurodegeneration · 2026-04-21
## **Molecular Mechanism and Rationale** The NAD+/SARM1 axis represents a critical metabolic checkpoint that coordinate
Score: 0.560 · neurodegeneration · 2026-04-21
## Mechanistic Overview Post-Translational Modification Codes Determine Interaction Specificity starts from the claim th
Score: 0.530 · pharmacology · 2026-04-21
## Mechanistic Overview CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial Priming Reversal starts from the cla
Score: 0.524 · neurodegeneration · 2026-04-21
## Mechanistic Overview Circadian Clock Epigenetic Desynchronization Window starts from the claim that modulating BMAL1/